Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), has successfully closed its $5.75 million underwritten public offering, marking a significant milestone in advancing its clinical development program. The transaction, which included 19,166,667 shares of common stock (or pre-funded warrants to purchase common stock in lieu thereof) priced at $0.30 per share, strengthens the company’s financial position to progress its innovative radiation sensitizer therapies.
Lucosky Brookman LLP served as legal counsel to WestPark Capital, Inc., the Sole Book-Runner in this strategic financing, which bolsters Shuttle Pharma’s ability to advance its clinical pipeline. The offering was conducted on a firm commitment basis pursuant to a registration statement on Form S-1 (File No. 333-284889) that was declared effective by the Securities and Exchange Commission on March 7, 2025.